Pages that link to "Q44499883"
Jump to navigation
Jump to search
The following pages link to Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study (Q44499883):
Displaying 50 items.
- How to tackle tremor - systematic review of the literature and diagnostic work-up (Q21129430) (← links)
- Missing pieces in the Parkinson's disease puzzle (Q22251063) (← links)
- The role of oxidative stress in Parkinson's disease (Q24307946) (← links)
- Available and emerging treatments for Parkinson’s disease: a review (Q24633444) (← links)
- Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment (Q24647141) (← links)
- Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor (Q24805917) (← links)
- Emerging approaches in Parkinson's disease - adjunctive role of safinamide (Q26740905) (← links)
- The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease (Q26745661) (← links)
- Dystonia and Tremor: The Clinical Syndromes with Isolated Tremor (Q26751639) (← links)
- Functional neuroimaging in Parkinson's disease (Q27013767) (← links)
- Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys (Q27316473) (← links)
- Parkinson's disease (Q28264391) (← links)
- Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials (Q28270780) (← links)
- TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial (Q28274460) (← links)
- Dopamine agonists in Parkinson's disease (Q28276692) (← links)
- Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease (Q28283547) (← links)
- Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan (Q28542989) (← links)
- N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data (Q30000089) (← links)
- Imaging psychogenic movement disorders (Q30446926) (← links)
- Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease? (Q30454441) (← links)
- Surrogate outcomes in neurology, psychiatry, and psychopharmacology (Q30473416) (← links)
- Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes (Q30480599) (← links)
- R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. (Q30483115) (← links)
- Longitudinal follow-up of SWEDD subjects in the PRECEPT Study (Q30578973) (← links)
- The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review (Q30635471) (← links)
- Neuroimaging in Parkinson disease: from research setting to clinical practice (Q30868628) (← links)
- Neuroimaging and therapeutics in movement disorders (Q30989947) (← links)
- Imaging in cell-based therapy for neurodegenerative diseases. (Q31015455) (← links)
- Human gene therapy and imaging in neurological diseases (Q31023442) (← links)
- The diagnosis of Parkinson's disease (Q31026806) (← links)
- The role of biomarkers and imaging in Parkinson's disease. (Q31041660) (← links)
- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease (Q33260250) (← links)
- The role of imaging in proof of concept for CNS drug discovery and development (Q33374793) (← links)
- Nonergot dopamine-receptor agonists for treating Parkinson's disease - a network meta-analysis (Q33604937) (← links)
- New small molecules for the treatment of Parkinson's disease (Q33636631) (← links)
- Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications (Q33708288) (← links)
- The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function (Q33897463) (← links)
- Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease (Q34027880) (← links)
- Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies (Q34078528) (← links)
- Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson's disease: study design and rationale. (Q34194102) (← links)
- Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study (Q34376763) (← links)
- LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease. (Q34415609) (← links)
- Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist (Q34504316) (← links)
- Seniors with Parkinson's Disease: Initial Medical Treatment (Q34508143) (← links)
- Ropinirole therapy for Parkinson's disease (Q34557072) (← links)
- Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease (Q34827117) (← links)
- Medical management of Parkinson's disease: focus on neuroprotection (Q35092165) (← links)
- A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease. (Q35147766) (← links)
- Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". (Q35148529) (← links)
- Agonizing over dopaminergic replacement therapy--lessons from animal models of Parkinson's disease (Q35212610) (← links)